載入...
Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection are one of the major advances in its medical treatment. The HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States, Europe, and Japan. When combined with peginterferon plus ribavi...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Baishideng Publishing Group Co., Limited
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3870547/ https://ncbi.nlm.nih.gov/pubmed/24379619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i47.8940 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|